Compare Gilead Sciences, Inc. (GILD) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vale SA — how do they compare? Gilead Sciences, Inc. trades at $135.94 (market cap $163.51B), while Vale SA trades at $14.23 (market cap $61.19B). The key difference: Gilead Sciences, Inc. is far larger — about 2.7× Vale SA's market cap, and Vale SA pays the higher dividend (8.58%). Which is the better fit depends on your goals.
| GILD | VALE | |
|---|---|---|
Market Cap | $163.51B | $61.19B |
Sector | Health | Basic Materials |
52-Week High | $155.80 | $17.82 |
52-Week Low | $108.22 | $9.53 |
Enterprise Value | $178.05B | $78.11B |
Dividend Yield | 2.49% | 8.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
VALE trades at $14.27, down 2.19% with a bearish technical signal. The company reported mixed Q1 2026 earnings, missing expectations with EPS of $0.44 versus $0.47 expected. Recent news highlights a $2.56 billion decarbonization investment and governance challenges with board disputes. Cash flow remains positive at $2.42B net for 2025, though revenue has declined from $43.8B in 2022 to $38.4B in 2025.
Analyst consensus is mixed with 40.5% buy ratings and a $17.50 price target suggesting 23% upside. Risks include volatile iron ore prices, rising debt-to-asset ratio to 24.66%, and execution of decarbonization investments. The stock offers value with P/E of 22.23 and EV/EBITDA of 7.33, but faces headwinds from margin compression and geopolitical tensions affecting operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
